PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024.
Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit
Date: Thursday, October 17th, 2024
Time: 10:30am
Webcast: https://m-vest.com/events/healthcare-10152024
Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference.
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn
CONTACT
Jeff Ramson
PCG Advisory
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-863-6893
| Last Trade: | US$0.48 |
| Daily Change: | -0.01 -2.78 |
| Daily Volume: | 691,277 |
| Market Cap: | US$3.860M |
October 15, 2024 September 24, 2024 August 22, 2024 August 21, 2024 August 12, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
